Los Angeles Biotechnology Network
  • Home
  • About
  • News
    • All LABN News
    • Trending LABN News
  • Jobs
    • All LABN Jobs
    • Post A Job
  • Subscribe
  • Contact
News Ticker
  • [ March 31, 2023 ] Product Manager – Cell and Gene Therapy – FUJIFILM – Santa Ana, CA Los Angeles Biotech Jobs
  • [ March 31, 2023 ] Medical Laboratory Scientist – Clinical Laboratory – Providence – Fullerton, CA Los Angeles Biotech Jobs
  • [ March 31, 2023 ] Senior Biostatistician – Providence – Irvine, CA Los Angeles Biotech Jobs
  • [ March 31, 2023 ] Postdoctoral Fellow – Computational Biology and Molecular Dynamics – City of Hope – Duarte, CA Los Angeles Biotech Jobs
  • [ March 31, 2023 ] QC Microbiology Associate II – B. Braun Medical Inc. – Irvine, CA Los Angeles Biotech Jobs
HomeLos Angeles Biotech NewsPharmaCyte Biotech Addresses Submission of IND and Recent FDA-Required Testing

PharmaCyte Biotech Addresses Submission of IND and Recent FDA-Required Testing

March 12, 2020 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on PharmaCyte Biotech Addresses Submission of IND and Recent FDA-Required Testing
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- #INDstatus--Dr. Gerald W. Crabtree addresses PharmaCyte's submission of its IND and recent FDA-required testing

Click to view original post

Previous

Global Research Nonprofit CureDuchenne Joins Pfizer to Host Free Webinar on Pfizer?s Advancement to Phase III Gene Therapy Clinical Trial

Next

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

Follow/Subscribe

POST A JOB
Tweets by LABioNetwork

Copyright © 2021 Biotech Networks, LLC

Want to Save Time?

Get Trending News & Jobs Delivered